Kappa opioid receptor (KOPR) is involved in many physiological functions and pharmacological responses such as analgesia, anti-pruritic effect, sedation, motor incoordination and aversion (Simonin et al., 1998; Liu-Chen, 2004). The cellular mechanisms following activation of KOPR involve in part Gi/o protein-dependent pathways (Law et al., 2000). Following KOPR activation, the receptor is phosphorylated and arrestins are recruited. Arrestins mediate agonist-dependent KOPR desensitization, internalization and down-regulation (Liu-Chen, 2004). In recent years, arrestins were found to initiate arrestin-dependent downstream signaling. Thus, agonist-promoted KOPR phosphorylation plays a pivotal role in KOPR regulation and signaling. Previous studies from our lab showed that in Chinese hamster ovary (CHO) cells stably transfected with the human KOPR (hKOPR), U50,488H induced phosphorylation (Li et al., 2002a); however, sites of phosphorylation were not determined. Using LC-MS/MS, our lab recently identified four residues (S356, T357, T363 and S369) to be the sites of U50,488H-promoted phosphorylation in the mouse KOPR (mKOPR) stably expressed in N2A cells (Chen et al., 2016). Antibodies were generated against phosphopeptides and purified and three antibodies were found to have high specificity for the mKOPR phosphorylated at S356/T357, T363 and S369, respectively (Chen et al., 2016). Our lab previously showed that while U50,488H promoted robust hKOPR phosphorylation and internalization, etorphine induced little phosphorylation and internalization, although both were potent full agonists in enhancing [35S]GTPγS (Li et al., 2002a; Zhang et al., 2002; Li et al., 2003). Etorphine caused lower levels of KOPR phosphorylation at all the four residues than U50,488H by immunoblotting with the phospho-specific antibodies (Chen et al., 2016). Using the SILAC (stable isotope labeling by amino acids in cell culture) approach, we have found that compared to etorphine, U50,488H promoted higher levels of single phosphorylation at T363 and S369 and double phosphorylation at T363+S369 and T357+S369 as well as triple phosphorylation at S356+T357+S369 (Chen et al., 2016). These results indicate that an above-threshold phosphorylation is required for KOPR internalization. It has been reported that KOPR is involved in neuronal differentiation and neurogenesis. In the first chapter, I focused on whether there are differences in the mechanisms underlying neurite outgrowth induced by U50,488H and etorphine. In the chapter 2, mechanisms of KOPR phosphorylation were characterized in detail using phospho-specific KOPR antibodies. Protein kinase C was found, for the first time, to be involved in agonist-promoted KOPR phosphorylation. The roles of PKC in behavioral effects induced by KOPR agonists in mice were examined. For the chapter 1, in Neuro2a mouse neuroblastoma cells stably transfected with the hKOPR (N2A-3HA-hKOPR), U50,488H robustly induced neurite outgrowth, but etorphine caused outgrowth to a much lower extent. G protein-dependent pathway was found to be involved in the actions of both agonists, but β-arrestin-dependent pathway was not. Inhibition of ERK1/2 phosphorylation decreased neurite outgrowth promoted by both agonists, indicating the roles of MAP kinase cascades in KOPR agonist-induced neuritogenesis. In contrast, β-arrestin2, 14-3-3ζ, GEC1 and Rap1 are not involved in U50,488H- or etorphine-promoted neurite outgrowth. Thus, the two agonists appear to share the same signaling pathways and the difference between two agonists is likely due to the lower efficacy of etorphine. For the chapter 2, U50,488H caused phosphorylation of the mKOPR at S356, T357, T363 and S369 in N2A cells stably transfected with FmK6H (FmK6H-N2A cells). NorBNI abolished U50,488H-induced KOPR phosphorylation at all four residues. GRKs (GRKs2, 3, 5 and 6) and PKCs were involved in U50,488H-mediated KOPR phosphorylation. In addition, PKC also participated in agonist-independent KOPR phosphorylation. This is the first time that PKC was shown to be involved in agonist-induced KOPR phosphorylation. We found that U50,488H caused KOPR phosphorylation at T363 and S369 in the mouse brain and PKC participated in phosphorylation of S369, but not T363, by using the PKC inhibitor chelerythrine (CHL). Thus, we further characterized effects of PKC inhibition on KOPR-mediated behaviors in CD1 mice. PKC was involved in KOPR-mediated sedation, motor incoordination and conditioned place aversion, but not analgesia and anti-scratching effect in mice. Studies in this thesis revealed the mechanisms of KOPR-mediated neurite outgrowth and KOPR-mediated phosphorylation and the involvement of PKC in KOPR-mediated pharmacological effects in vivo. These studies push the frontier of molecular pharmacology of the KOPR, which may be useful for development of KOPR agonists for therapeutic use. / Pharmacology

Millions of people in the US currently suffer from chronic pain but available therapeutics do not provide effective chronic pain treatment. Opiate therapy is still the gold standard for chronic pain management with detrimental side effects, such as tolerance, addiction, constipation, and respiratory depression that limit their therapeutic potential. Opiates exert their positive and negative effects by activating the μ opioid receptor (MOR). Conversely, the κ opioid receptor (KOR) has been shown to modulate the tolerance and addiction produced by MOR agonists and is also involved in mood modulation (anxiety and depression). Therefore, blocking KOR activation results in positive effects against opiate side effects and stress-related depression. Dynorphin A (Dyn A) is the endogenous opioid peptide for the KOR. Structure-activity relationship (SAR) studies were carried out to develop a KOR selective antagonist based on the Dyn A structure. A minimum Dyn A pharmacophore with improved stability, no cell toxicity, and antagonist activity was discovered. Peptidomimetic enkephalin analogues previously developed in our group as MOR and δ opioid receptor (DOR) agonists have shown multifunctional activity, with MOR/DOR agonist and KOR antagonist activities. To our knowledge, this finding is first of its class for the opioid receptors. Novel design and synthesis of KOR selective ligands based on our multifunctional enkephalin analogues was done. Successful peptide synthesis resulted in analogues with high stability in rat plasma and no cell toxicity.

L'addiction est une affection chronique emmaillée de rechutes, caractérisée principalement par des comportements compulsifs de recherche et de consommation de drogue. Il s'agit d'une pathologie grave et fréquente. Les sujets qui parviennent à se désengager de ces compulsions sont considérés comme abstinents. Les études épidémiologiques montrent que l'abstinence, notamment pour les opiacés est fortement associée à une prévalence accrue de la dépression. Le but de mon travail de thèse était d'aborder spécifiquement la cooccurrence des troubles dépressifs et addictifs. J'ai participé à l'élaboration d'un modèle murin de cette comorbidité, et nous nous sommes focalisés sur l'addiction aux opiacés, en particulier l'héroïne. Suite à un traitement chronique par l'héroïne et au cours de l'abstinence paraissent progressivement des comportements apparentés à la dépression. Ce traitement chronique à l'héroïne modifie le fonctionnement du système sérotoninergique et l'activité du récepteur opioïde kappa (Article publié: Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-­like behaviors during heroin abstinence). Les déficits comportementaux observés peuvent être prévenus et reversés par un traitement antidépresseur ciblant le system sérotoninergique ou en inhibant l'activité du récepteur opioïde kappa avec un antagoniste, dans des portions similaires (Manuscript submis: Kappa opioid receptor antagonism prevents and reverses heroin abstinence-­induced social deficit with similar efficacy compared to chronic antidepressant treatment). Notre étude nous permet de proposer que le récepteur opioïde kappa constitue un acteur majeur à l'interface de l'addiction et de la dépression(Revue publié: The kappa opioid receptor: from addiction to depression, and back). / Addiction is a chronic, relapsing disorder and is mainly described as compulsive craving and consumption of a drug in spite of adverse consequences. Individuals who have achieved to refrain from such compulsive behaviour are considered abstinent, but present symptoms reminiscent of depression. Epidemiological studies report that abstinence, particularly from opiates, strongly associates with higher prevalence of depression. Aim of my thesis was to specifically address the co-­occurrence of opiate addiction and major depression in preclinical research. Thus, I have contributed to develop a mouse model of opiate abstinence, and in particular extend our model of morphine abstinence to heroin. Following exposure to escalating doses of heroin, abstinent mice progressively exhibit a depressive-­like phenotype, revealed by low sociability., and show altered serotonergic and kappa opioid receptor signaling (Published article: Distinct mu, delta and kappa opioid receptor mechanisms underlie low sociability and depressive-­like behaviors during heroin abstinence).Importantly, these behavioural deficits can be both prevented and reversed by antidepressant treatment targeting serotonergic signaling, or inhibiting the activity of the kappa opioid receptor withan antagonist, with similar efficacy (Submitted article: Kappa opioid receptor antagonism prevents and reverses heroin abstinence-­induced social deficit with similar efficacy compared to chronic antidepressant treatment). Altogether, our results allow us to propose the kappa opioid receptor is a major player at the interface of addiction and depression (Published review: The kappa opioid receptor: from addiction to depression, and back).

This thesis is comprised of two parts. In the first part, we investigated a) the pharmacology of GNTI, a selective kappa opioid receptor antagonist, as a scratch-inducing compound in mice and b) possible mediators and receptors that may be involved in GNTI-induced scratching (itch). We studied if GNTI induces scratching through opioid, histamine, gastrin-releasing peptide (GRP) and/or muscarinic M1 receptors. In the second part, we established similarities and differences between pain and itch using GNTI-induced scratching and formalin-induced nociception models in mice. We found that GNTI (0.03-3 mg/kg, s.c., behind the neck) induces compulsive and vigorous scratching behavior in a dose-dependent manner. A standard submaximal dose (0.3 mg/kg) of GNTI caused animals to scratch 500-600 times in a 30 min observation period. Intrathecal (i.t.) or intraperitoneal (i.p.) administration of GNTI did not elicit scratching behavior. Duration of action of GNTI was 60-70 min and tolerance to the repetitive behavior did not develop. C-fos expressing neurons, in response to GNTI injection, were localized on the lateral side of the superficial layers of the dorsal horn of the cervical spinal cord. Compound 48/80, a chemically different pruritogen, evoked c-fos expression in neurons which are located on the lateral side of the superficial layer of the dorsal horn. These data suggest that both GNTI and compound 48/80 activate a group of sensory neurons located on the lateral side of lamina I and II. Pretreating (at -20 min) and posttreating (at +5 min) mice with the kappa opioid receptor agonist, nalfurafine (0.001-0.03 mg/kg, s.c.), significantly attenuated scratching induced by GNTI (0.3 mg/kg). These effects were not a consequence of behavioral depression. Tolerance did not develop to the anti-scratch activity of nalfurafine. Pretreating mice with nalfurafine (0.02 mg/kg) prevented both GNTI- and compound 48/80-provoked c-fos expression. Our c-fos results suggest that the preclinical antipruritic activity of nalfurafine occurs at the spinal level. Moreover, our results reinforce the need to evaluate nalfurafine as a potentially useful antipruritic in human conditions involving itch. GNTI still elicited excessive scratching in mice lacking mu, delta or kappa opioid receptors, respectively, as well as in mice pretreated with either naloxone or norbinaltorphimine. The H1 receptor antagonist, fexofenadine, or the H4 receptor antagonist, JNJ 10191584, did not attenuate GNTI-induced scratching. Also, pretreating mice with the peptide GRPR antagonist, [D-Phe6]bombesin(6-13) methyl ester, or the non-peptide GRPR antagonist, RC-3095, did not antagonize scratching induced by GNTI. Furthermore, GRPR mRNA levels did not change in response to GNTI injection. Telenzepine, a standard M1 receptor antagonist, had no marked effect against GNTI-elicited scratching, however (unexpectedly) McN-A-343, an M1 receptor agonist, attenuated this behavior in a dose-dependent manner. In the second part of our studies, we found that pretreating mice with lidocaine (i.d., behind the neck) inhibits GNTI-induced scratching and prevents GNTI-provoked c-fos expression in the dorsal horn of the spinal cord. Similarly, lidocaine (i.d., hind leg) inhibits formalin-induced nociception as well as formalin-provoked c-fos expression. While injection (s.c.) of formalin to the face of mice induced only wiping (indicating pain) by forepaws of the injection side, injection (s.c.) of GNTI to the face elicited grooming and scratching (indicating itch). In contrast to formalin, GNTI did not induce c-fos expression in the trigeminal nucleus suggesting that pain and itch sensations are projected differently along the sensory trigeminal pathway. In short, our main results indicate that a) the scratch-inducing activity of GNTI is not mediated by opioid, histamine or GRP receptors; b) kappa opioid receptors are involved, at least in part, in the inhibition of itch sensation and thus, on the basis of our results, nalfurafine holds promise as a potentially useful antipruritic in human conditions involving itch; and c) agonism at M1 receptors inhibits GNTI-induced scratching therefore the M1 receptor may be a key target for antipruritic drug development. / Pharmacology

This thesis is comprised of three parts. In the first part, we investigated zyklophin, a novel selective short-acting kappa opioid receptor (KOPR) antagonist, and its effects on scratching behaviors in Swiss-Webster mice. We investigated whether zyklophin was able to induce scratching in a dose-dependent fashion, and whether this scratching behavior could be blocked by pretreatment with nor-binaltorphimine (norBNI). We also used KOPR -/- mice to further clarify the role of the KOPR in this behavior. In the second part, we examined the role of the divergent amino acid at position 6.58 in the mu opioid receptor (MOPR) and the KOPR on the binding of beta-funaltrexamine ß-FNA). ß-FNA is an irreversible antagonist at the MOPR and a reversible agonist at the KOPR. Utilizing the recently published crystal structures of the MOPR and KOPR, we collaborated with Dr. Lei Shi, who employed molecular modeling to choose a residue in transmembrane helix 6 (TM6) to mutate at the same position in MOPR and KOPR. We then characterized the mutants by performing [3H]diprenorphine binding, competition binding by unlabeled β-FNA, irreversible ß-FNA binding and [35S]GTPγS binding. In the third part, we investigated the concept of functional selectivity, or ligand bias, at the KOPR. We studied 23 different KOPR agonists in vitro using [35S]GTPγS binding as a measure of G protein activation and the on-cell Western (OCW) as a measure of ß-arrestin-mediated receptor internalization at the human KOPR (hKOPR), and from the results, chose 13 ligands to study at the mouse KOPR (mKOPR). We then selected biased ligands from the in vitro mKOPR results and studied their effects on scratching behavior, inhibition of pain behaviors and dysphoria as measured by the conditioned place aversion (CPA) test. We predicted that the G biased ligand would produce analgesia and anti-scratching effects at lower doses than would produce aversion in the CPA test, since analgesia has been shown to be G protein mediated and CPA has been shown to be arrestin mediated. Our first set of studies revealed that zyklophin (0.1, 0.3 and 1 mg/kg, s.c., behind the neck), induced vigorous scratching in a dose-dependent manner. 0.3 mg/kg zyklophin induced 150 scratches over a 30 minute period. The scratching was not blocked by pretreatment with 20 mg/kg norBNI (i.p.) 18-20 hours before injection of 0.3 mg/kg zyklophin s.c. in the nape of the neck. The scratching also persisted in KOPR -/- mice, in which the absence of the KOPR was confirmed by [3H]U69,593 binding (2 nM). In our second set of studies, we mutated the lysine at position 303 in the MOPR to glutamic acid (K303E), and the glutamic acid at the equivalent position in the KOPR to lysine (E297K). We transfected these mutant receptors into mouse neuroblastoma (N2A) cells. We found that the mutations had no effect on [3H]diprenorphine binding affinity or competition binding with [3H]diprenorphine and β-FNA indicating a functional intact opioid receptor. The mutations also did not affect [35S]GTPγS binding EC50 or Emax values. The mutation K303E in the MOPR reduced irreversible binding by 2/3 compared to the wildtype MOPR. Finally, we found that there were several ligands that displayed bias at the hKOPR and the mKOPR. At the hKOPR, using dynorphin A as the reference ligand to calculate bias, ICI-199441 was the only G biased ligand, while enadoline, nalbuphine, pentazocine, salvinorin A, tifluadom and butorphanol were arrestin-biased. At the mKOPR, only salvinorin B methoxymethyl ether (MOM-SalB) was G-biased, and salvinorin B ethoxymethyl ether (EOM-SalB), ICI-199441, U50,488H, nalfurafine and 12-epi-salvinorin A (12epiSalA) were ß-arrestin-biased. Enadoline and salvinorin A were slightly arrestin biased with respect to dynorphin A. From the in vitro data at the mKOPR, we selected MOM-SalB as our G biased ligand, U50,488H as our arrestin biased ligand and additionally chose to investigate nalfurafine due to its use in clinical studies. We hypothesized that U50,488H and nalfurafine would produce aversion at lower doses than analgesia or anti-pruritic effects. We found that nalfurafine was the only ligand studied to have a separation between doses that produced analgesia and anti-scratching effects, with A50 values of 5.8 and 8 μg/kg, respectively, and only produced significant dysphoria at a dose of 20 μg/kg. U50,488H and MOM-SalB produced dysphoria at all doses tested (0.25-10 mg/kg and 0.01-0.3 mg/kg, respectively). U50,488H produced a dose-dependent analgesia and anti-scratching with A50 values of 0.58 mg/kg and 2.07 mg/kg, respectively. MOM-SalB was more potent than U50,488H in producing dose-dependent analgesia and anti-scratching, with A50 values of 0.017 mg/kg and 0.070 mg/kg, respectively. Therefore, we concluded that the in vitro bias is not able to accurately predict in vivo behaviors, and nalfurafine is the first selective full agonist at the KOPR to show ligand bias in vivo. / Pharmacology

Orientadores: Claudia Herrera Tambeli, Maria Cecilia F. A. Veiga / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Odontologia de Piracicaba / Made available in DSpace on 2018-08-03T22:56:59Z (GMT). No. of bitstreams: 1 Clemente-Napimoga_JulianaTrindade_M.pdf: 904782 bytes, checksum: 55d51f81e2ba465f145751f287246951 (MD5) Previous issue date: 2004 / Resumo: Este estudo avaliou as diferenças sexuais na resposta nociceptiva induzida pela administração de formalina na articulação temporomandibular (ATM) com ou sem a co-administração do U50,488 (agonista do receptor opióide capa). As fases do ciclo estral das fêmeas foram citologicamente determinadas e apenas aquelas que apresentavam-se na fase diestro ou proestro, e machos foram incluídos. A formalina induziu um comportamento nociceptivo maior nas fêmeas em diestro do que nas fêmeas em proestro ou machos. O U50,488 reduziu significativamente as respostas nociceptivas induzidas pela formalina, e esta redução foi maior nas fêmeas, especialmente nas fêmeas da fase diestro do ciclo estral. A injeção do U50,488 na ATM contralateral não afetou na magnitude do comportamento induzido pela formalina, e o pré-tratamento com o antagonista seletivo do receptor opióide capa nor-binaltorphimine (norBNI) na ATM ipsilateral reduziu os efeitos antinociceptivos do U50,488. Estes resultados demonstram a ação dos receptores opióides capa periféricos na modulação da dor inflamatória. Além disso, considerando que os níveis plasmáticos dos hormônios ovarianos são baixos durante a fase diestro, estes resultados são consistentes com a hipótese de que os hormônios sexuais femininos podem ter uma ação analgésica na redução da dor inflamatória induzida pela formalina, assim como, também ter uma ação anti-analgésica nos efeitos mediados pelos receptores opióides capa / Abstract: This study examined sex differences in nociceptive responses induced by intra-temporomandibular joint (TMJ) formalin with and without co-administration of the ?-opioid receptor agonist U50,488. The estrous phase of females was cytologically determined; only those in either proestrus or diestrus, and males, were included. Formalin elicited significantly greater nociceptive behavior in diestrus females than in either proestrus females or males. U50,488 significantly reduced formalin nociceptive responses, and this reduction was significantly greater in females, especially in the diestrus phase of the estrous cycle. U50,488 injection into the contralateral TMJ failed to affect the magnitude of formalininduced behavior, and preinjection of the selective kappa-opioid receptor antagonist nor-binaltorphimine (nor-BNI) into the ipsilateral TMJ significantly reduced the antinociceptive effect of U50,488. These findings support a role for peripheral kappa-opioid receptors in the modulation of inflammatory pain. Furthermore, since plasma levels of ovarian hormones are lowest during diestrus, these findings are consistent with the suggestion that female sex hormones may play an analgesic role in reducing formalin-induced inflammatory pain, and may also play an anti-analgesic role, at least in ?-mediated effects / Mestrado / Fisiologia Oral / Mestre em Odontologia

Chronic postoperative pain impacts millions of individuals worldwide that undergo a variety of surgical procedures. Opioids remain the mainstay analgesics of acute and perioperative pain; however, prolonged opioid therapy may lead to life-threating adverse effects, tolerance, dependence, and addiction. Therefore, unraveling the cellular mechanisms that drive persistent pain states and opposing endogenous analgesia provided by opioid receptor signaling, may lead to novel analgesics. Evidence suggests that tissue injury leads to increased sensitization of the spinal cord nociceptive neurons which increases susceptibility to chronic pain via an N-methyl-D-aspartate (NMDA) receptor activation of calcium-sensitive adenylyl cyclase isoform 1 (AC1). This phenomenon, named latent pain sensitization (LS), is mediated by a compensatory response of endogenous inhibitory systems. In this dissertation, we test the hypothesis that surgical insult promotes prolonged activation of kappa opioid receptors (KOR) which mask LS via attenuation of pro-nociceptive AC1 signaling pathways in both male and female animals. We employed a murine model of chronic postoperative pain that promotes LS in the spinal cord and closely resembles the phenotypic features of postoperative pain in human subjects. When behavioral signs of hyperalgesia resolved, we targeted spinal opioid receptor systems and pronociceptive modulators with intrathecal delivery of selective pharmacological antagonists and assessed behavioral signs of hyperalgesia and spinal nociceptive sensitization. We propose that LS is kept in remission by a long-lasting compensatory response of tonic endogenous KOR signaling that hinders a pronociceptive LS pathway that includes not only AC1 but also two downstream targets: protein kinase A (PKA) and exchange protein activated by cAMP (Epac1/2) - in a sex-dependent manner. Our results propose new therapeutic targets for the management of persistent postoperative pain and underscore the importance of tailoring sex-specific pain management strategies.

Salvia divinorum is a hallucinogenic sage used to treat illness by the Mazatec Indians of Mexico. Salvinorin A (1a), a neoclerodane diterpenoid isolated from the plant, is a potent, selective agonist at the kappa opioid receptor (KOR), and is the first non-nitrogenous opioid. The plant is used recreationally as a hallucinogen, but is unpopular due to its dysphoric effects. 1a has been prohibited in Australia under an invalid systematic name. An early report of psychoactive alkaloids in S. divinorum proved to be irreproducible. Similarly, tests in mice suggesting the presence of psychoactive compounds other than 1a were confounded and therefore unreliable. In this work, an improved isolation method for 1a was developed, using filtration through activated carbon to decolourise the crude extract. Six new diterpenoids were isolated: salvinorins D–F (1d–1f) and divinatorins A–C (28a–28c). Five known terpenoids not previously reported from this species were also isolated. The structure–activity relationships of 1a were evaluated via selective modifications of each functional group. Useful synthetic methods are reviewed, including the first thorough review of furanolactone hydrogenations. Testing of the derivatives at the KOR suggests that the methyl ester and furan ring of 1a are required for activity, but that the lactone and ketone functionalities are not. Other compounds from S. divinorum did not bind to the KOR, suggesting that 1a is the plant’s active principle.

L’addiction ou dépendance aux substances psychoactives est une affection chronique, fréquente et grave, émaillée de rechutes et de périodes d’abstinence. Les études épidémiologiques montrent que l’abstinence aux opiacés est fortement associée à une prévalence accrue de la dépression. Nous résumons ici les principaux aspects cliniques de la dépendance aux opiacés et de la dépression, en détaillant leurs mécanismes physiopathologiques. Puis, nous présentons notre modèle d’abstinence aux opiacés chez la souris. Suite à un traitement morphinique chronique et au cours de l’abstinence apparaissent progressivement des comportements apparentés à la dépression. Ce traitement morphinique modifie profondément le fonctionnement du système sérotoninergique, notamment dans le noyau du raphé dorsal. De plus, les déficits comportementaux observés peuvent être prévenus par un traitement chronique par la fluoxétine, un antidépresseur ciblant ce système. Nous avons généralisé ce modèle à l’héroïne, un autre opiacé illicite. Nous avons révélé par des approches génétiques de délétion constitutive et conditionnelle les rôles distincts des 3 récepteurs opioïdes (mu, delta et kappa) lors de l’abstinence à l’héroïne. Enfin, nous avons initié une étude de caractérisation, à l’échelle de l’ensemble du génome, des adaptations transcriptomiques (ARN messagers et micro-ARN) dans le noyau du raphé dorsal au cours de l’abstinence à l’héroïne et du traitement antidépresseur. Ce travail devrait permettre d’améliorer notre compréhension des mécanismes neurobiologiques à l’œuvre dans la comorbidité entre dépendance aux opiacés et dépression et pourrait suggérer de nouvelles pistes thérapeutiques. / Addiction is a chronic, frequent and serious brain disease, with relapse alternating with abstinence periods. Epidemiological studies show that abstinence, notably from opiates, is strongly associated with depression.Here we present the main clinical aspects of opiate addiction and depression, and most recent advances in molecular pathophysiology of both disorders. Then, we present our mouse model of opiate abstinence. Following chronic morphine exposure, depressive-like behaviours progressively emerge. Morphine treatment profoundly disrupts serotonergic signalling, notably in the dorsal raphe nucleus. In addition, behavioural deficits can be prevented by chronic treatment with fluoxetine, an antidepressant targeting serotonergic neurons. We then generalized our mouse model to heroin, another major illicit opiate. Using constitutive and conditional knockout strategies, we documented distinct roles for all 3 opioid receptors (mu, delta and kappa) in heroin abstinence. Finally, we initiated a large-scale analysis of transcriptomic regulations (mRNA and micro-RNA) occurring in our model as a function of heroin abstinence and fluoxetine treatment.These studies should reveal an unforeseen contribution of the dorsal raphe nucleus to addiction. They should uncover new molecular mechanisms underlying depressive-like behaviors in mice during opiate abstinence and thus put forward new therapeutic targets in humans.

Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2015-10-13T12:34:40Z No. of bitstreams: 1 Ana Isabel Reis Nascimento. Participação...2015.pdf: 1631129 bytes, checksum: d14aa063c882bb96ee29f85751abf2e6 (MD5) / Approved for entry into archive by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2015-10-13T12:34:59Z (GMT) No. of bitstreams: 1 Ana Isabel Reis Nascimento. Participação...2015.pdf: 1631129 bytes, checksum: d14aa063c882bb96ee29f85751abf2e6 (MD5) / Made available in DSpace on 2015-10-13T12:34:59Z (GMT). No. of bitstreams: 1 Ana Isabel Reis Nascimento. Participação...2015.pdf: 1631129 bytes, checksum: d14aa063c882bb96ee29f85751abf2e6 (MD5) Previous issue date: 2015 / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Alguns estudos sugerem que as vias opioidérgicas centrais parecem desempenhar um papel regulatório no controle da ingestão de água e sal em mamíferos. As ações dos opioides centrais sobre a regulação do controle hidroeletrolítico são mediadas por vários dos subtipos de receptores opioides. O papel dos receptores delta e kappa-opioides centrais neste processo não está adequadamente elucidado sendo necessário mais estudos que o esclareçam. Objetivo: Este estudo investigou o envolvimento dos receptores delta e kappa-opioides centrais no apetite por sódio em ratos depletados deste íon e em rato ativados centralmente com angiotensina. Material e Métodos: Foram utilizados ratos Wistar (270 ± 20 g), submetidos à cirurgia estereotáxica para implante de cânula guia no ventrículo lateral esquerdo (VL), no órgão subfornical (OSF), no núcleo preóptico mediano (MnPO) e no núcleo basolateral da amígdala (BLA). No protocolo de depleção de sódio os animais foram submetidos à injeção subcutânea de furosemida combinada com dieta hipossódica quatro dias após a cirurgia. Neste modelo de estudo os animais receberam injeção intracerebroventricular (i.c.v.) do antagonista delta-opioide naltrindole no quinto dia pós-cirúrgico, nas doses de 5, 10 e 20 nmol/2 μL e do antagonista kappa-opioide, norbinaltorfimina, injetado no OSF, MnPO e BLA, nas doses de 0,5, 1,0 e 2,0 nmol/0,2 μL.. O agonista específico para os receptores delta-opioides, deltorfina II (2,5, 5,0, 10 e 20 nmol/2 μL), foi injetado i.c.v. em animais depletados de sódio pré-tratados com naltrindole na dose de 20 nmol/2 μL e em animais repletos de sódio na dose de 20 nmol/2 μL. O agonista kappa-opioide, ICI199,441 (2,0 nmol/0,2 μL) foi injetado no OSF, MnPO e BLA em animais depletados de sódio pré-tratados com norbinaltorfimina 2,0 nmol/0,2 μL e em animais repletos de sódio na dose de 2,0 nmol/0,2 μL. Bebedouros de água destilada (H2Od) e de salina foram introduzidos nas caixas15 minutos após a injeção central e tiveram seus volumes monitorados nos tempos 5, 10, 15, 30, 45, 60, 90 e 120 minutos, após a colocação dos bebedouros. No protocolo de ativação angiotensinérgica central, quarto dia após a cirurgia os animais sofreram administração i.c.v. de naltrindole (5, 10 e 20 nmol/2 μL) 15 minutos antes de receberem injeções de angiotensina II na dose de 10 ng/2 μL. Os bebedouros de H2Od e de solução salina foram introduzidos nas caixas logo após a segunda injeção e tiveram seus volumes monitorados nos tempos 5, 10, 15, 30, 45, 60, 90 e 120 minutos, após a colocação dos bebedouros. Para verificar a especificidade de ação dos antagonistas opioides os animais foram submetidos aos testes de sobremesa, campo aberto e medida da pressão arterial. A análise estatística utilizada foi ANOVA modelo misto para medidas repetidas seguida do pós-teste de Bonferroni para múltiplas comparações dos volumes ingeridos e teste “t” de Student não pareado para análise dos testes de comportamento, através do programa GraphPad Prism 6.0. Resultados: Os grupos de ratos que receberam injeções i.c.v. de naltrindole após depleção de sódio e ativação angiotensinérgica central, apresentaram redução estatisticamente significante na ingestão de salina quando comparados ao grupo de animais controles. Os ratos que receberam injeção de norbinaltorfimina no OSF, MnPO e BLA após depleção de sódio apresentaram redução estatisticamente significante na ingestão de salina quando comparados ao grupo de animais controles. A estimulação dos receptores delta-opioides em animais repletos de sódio aumentou a ingestão de salina hipertônica. Conclusões: Os dados presentes sugerem que os receptores delta-opioides centrais e os receptores kappa-opioides localizados no OSF, MnPO e BLA parecem desempenhar papel fundamental na expressão do comportamento de aquisição de sal em ratos que sofreram depleção de sódio e ativação central do apetite por sódio induzido pela via angiotensinérgica. / Central opioid pathways seem to have an important role on the control of water and salt intake in mammals, and brain opioid peptides may influence hydroelectrolyte balance through a myriad of actions mediated by distinct opioid receptors. The specific role of central delta and kappa-opioid receptors (DOR and KOR) in this process is far from being fully understood. In the present work, we investigated the role of those receptors in the control of water and salt intake, in sodium-depleted rats and rats with activation central angiotensinergic. Method: Wistar male rats (250 ± 20 g) were used in the experiment after stereotaxic cannulation of the VL left, SFO, MnPO and BLA. To study the effect of the blockade of central DOR and KOR on water and salt intake in rats were sodium depleted by the concomitant use of s.c. injections of furosemide and were kept in hypossodic diet, five days after surgery. In the sixth day, they received i.c.v. injections of a selective delta-opioid receptor antagonist (naltrindole) at the doses of 5, 10 and 20 nmol/2 μL and injections in the SFO, MnPO and BLA of a selective kappa-opioid receptor antagonist (norbinaltorphimine) at the doses of 0.5, 1.0 and 2.0 nmol/0.2 μL. The specific agonist for delta-opioid receptor deltorphin II (2.5, 5.0, 10 and 20 nmol / 2 !L) was injected i.c.v. in animals depleted pretreated with sodium naltrindole at the dose 20 nmol /2 !L . The kappa-opioid agonist, ICI199,441 (2 nmol /0.2 !L) was injected into the SFO, MnPO and BLA in animals depleted pretreated with sodium norbinaltorphimine 2.0 nmol / 0.2 !L. Bottles containing water or hypertonic saline solution were introduced into the cages 15 min after the central administration. To study the effect of the blockade of central DOR and KOR on water and salt intake in animals after central angiotensinergic stimulation, the animals received intracerebroventricular injections of naltrindole at the doses of 5, 10 and 20 nmol/2 μL 30 min before receiving central injections of angiotensin II at the dose of 10 ng/2 μL. In this case, bottles containing water or hypertonic saline solution were introduced into the cages immediately after the central administration of angiotensin II. Water and salt intake were recorded for the next 2 hours after the introduction of the bottles into the cages. To verify the specificity of action of opioid antagonists animals were submitted to the dessert test, open field and measurement of blood pressure. Data were analyzed by Two-Way ANOVA mixed model followed by Bonferroni as post-hoc test. Results: The groups of rats that received i.c.v. injections naltrindole after sodium depletion and central angiotensinergic activation, showed a statistically significant reduction in salt intake when compared to control animals group. Rats receiving norbialtorphimine injection in the SFO, MnPO and BLA after sodium depletion showed a statistically significant reduction in salt intake when compared to control animals group. The stimulation of delta-opioid receptors in animals full of sodium increased intake of hypertonic saline. Conclusions: The present data suggest that the delta-opioid receptors central, and the kappa-opioid receptors located in the SFO, MnPO and BLA appear to play a key role in the expression of the salt acquisition behavior in rats with sodium appetite.